50 results about "Chloroquine" patented technology

The invention provides a preparation method and application of nano protein, and the preparation method comprises the following steps: adopting lactoferrin as a carrier, reducing by using a reducing agent, stirring with DNA enzyme and a DNA chimeric agent, and obtaining the nano protein by using a nano precipitation method, the preparation method comprises the following steps: by taking lactoferrin as a nano-carrier, opening a folding structure of the lactoferrin by utilizing glutathione, then adding chloroquine and DNA enzyme, and finally, accelerating the reformation of a disulfide bond of the lactoferrin by stirring. On one hand, a DNA chimeric agent chloroquine is utilized to maintain the eDNA configuration in the biological membrane to be B type, and on the other hand, the mycobacterium tuberculosis biological membrane is efficiently disintegrated based on the enzymatic hydrolysis capability of DNA enzyme; the nano protein can efficiently grab iron ions at a focus part based on the iron chelation characteristic of the nano protein, so that bacteria die due to iron deficiency, and the bioavailability of DNA enzyme and the hydrolysis efficiency of a biological membrane can be improved to a great extent.

The invention discloses a hydroxychloroquine sulfate syrup without a bacteriostatic agent and a preparation method of the hydroxychloroquine sulfate syrup, and relates to the technical field of pharmaceutical preparations. The preparation method of the hydroxychloroquine sulfate syrup comprises the following steps: (1) adding cane sugar in a formula ratio into water, and heating until the cane sugar is completely dissolved to obtain syrup; (2) adding hydroxychloroquine sulfate according to a formula ratio into the syrup obtained in the step (1), and completely dissolving; and (3) adjusting the pH value to 4-6 to obtain the hydroxychloroquine sulfate syrup without the bacteriostatic agent. The hydroxychloroquine sulfate syrup prepared by the preparation method can realize good stability and antibacterial efficacy without adding a bacteriostatic agent, has good taste, is higher in safety, and is more suitable for children to use.

The invention discloses a double sulfur vacancy SV-Bi2S3 / SV-ZnIn2S4 heterojunction photocatalyst as well as a preparation method and application of the double sulfur vacancy SV-Bi2S3 / SV-ZnIn2S4 heterojunction photocatalyst. According to the double-sulfur-vacancy SV-Bi2S3 / SV-ZnIn2S4 composite photocatalyst, the existence of the sulfur vacancy in a composite material is proved through electron paramagnetic resonance. In addition, a scanning electron microscope, X-ray diffraction and Fourier infrared analysis show that the results show that the composite materials interact with one another and have tight interface contact. In addition, the double-sulfur-vacancy SV-Bi2S3 / SV-ZnIn2S4 composite photocatalyst prepared by the preparation method disclosed by the invention has the characteristics of good structural stability and recyclability, so that the treatment cost is greatly reduced. Meanwhile, the catalyst is low in cost, chloroquine phosphate in the wastewater can be quickly decomposed and converted, the wastewater treatment efficiency is greatly improved, and the requirement of large-scale industrial application is met.

The invention belongs to the technical field of biological medicine and molecular biology, and relates to application of TRIM38 as a therapeutic target and a prognostic marker of breast cancer. Research accidentally finds that TRIM38 can inhibit proliferation and metastasis of breast cancer, and further research shows that TRIM38 can block autophagy flow of breast cancer cells. Meanwhile, the TRIM38 can have a combined anti-tumor effect with autophagy inhibitors such as hydroxychloroquine and the like. In addition, the research shows that the TRIM38 can also be used as a prognostic marker of a breast cancer patient.

AAV vectors are ideally suited for long-term delivery of a combination of broadly neutralizing antibodies to achieve sterilizing immunity to HIV. Unfortunately, host immune responses to the delivered antibody have severely limited the efficacy. The TLR9 pathway has been identified in initiating adaptive immune responses against AAV and delivered bNAbs. To enhance this strategy, we validated Hydroxychloroquine, a known drug inhibitor of the TLR9 pathway, as a pretreatment to AAV delivery to avoid anti-drug antibody responses. TLR9 signaling inhibition was validated using a HEK-Blue hTLR9 reporter cell line and CpG stimulation. Hydroxychloroquine was also validated in a 3-macaque trial where AAV9-3BNC117 and AAV9-10-1074 were administered along with 3 doses of hydroxychloroquine once a week starting 1 week before AAV inoculation. Unlike historical controls, where 3BNC117 and 10-1074 expression is lost within the first 4-5 weeks, 2 macaques maintained 10-1074 expression and 1 macaque maintained 3BNC117 for the duration of the trial. Anti-3BNC117 antibodies were only observed in 2 of the 3 macaques and were significantly delayed. Anti-10-1074 antibody responses were a log lower than typically observed in historic controls. The use of hydroxychloroquine as a pretreatment for AAV inoculation is a promising strategy. The significant decrease in anti-10-1074 antibody levels and the successful delivery of 10-1074 in 2 macaques and 3BNC117 in 1 macaque was very encouraging. Extending the dosage of hydroxychloroquine beyond 3 doses may be sufficient to observe long-term bNAb expression in all animals and further decrease ADA responses. Together, these data suggest that the short-term treatment of hydroxychloroquine at the time of AAV inoculation has a meaningful impact on tolerance induction to our AAV-delivered bNAbs.

The invention provides a preparation method and application of a directional degradation liquid, and the preparation method comprises the following steps: adopting natural protein as a carrier, reducing by a reducing agent, and carrying out Michael addition reaction on the reduced natural protein, coupling agent modified DNA enzyme and chloroquine to obtain the directional degradation liquid, compared with the prior art, natural cationic glycoprotein lactoferrin is adopted as a carrier, surface charges of the lactoferrin are mostly distributed as positive charges under physiological conditions, and the lactoferrin can be rapidly and directionally enriched to a bacterial biofilm carrying a large number of negative charges through electrostatic interaction; under the action of a Michael addition reaction, lactoferrin, DNA enzyme and chloroquine are prepared into a directional degradation solution, a nucleic acid intercalator chloroquine is utilized to maintain eDNA configuration in a biological membrane to be a B type, and based on the enzymatic hydrolysis capacity of the DNA enzyme, the bacterial biological membrane is efficiently disintegrated, and the bacterial drug sensitivity is improved.

The present invention discloses a protective agent for endogenous iron death inhibitory protein in sheep sperm, a protective method and an application thereof. The protective agent for endogenous iron death inhibitory protein in sheep sperm comprises the following components: Tris, citric acid, glucose, chloroquine, glycerol, a mixture of penicillin-streptomycin, egg yolk liquid and ultrapure water, and the above substances are dissolved in the ultrapure water. The present invention also provides a method for protecting endogenous iron death inhibitory protein in sheep sperm, comprising the following steps: preparing an endogenous iron death inhibitory protein protective agent for sheep sperm; semen collection; diluting semen with an endogenous iron death inhibitory protein protective agent for sheep sperm; and freezing semen. The present invention also provides an application of an endogenous iron death inhibitory protein protective agent for sheep sperm. The present invention can protect the iron death inhibitory protein during the freezing recovery process, ensure the expression level of the iron death inhibitory protein, ensure the sperm motility and the integrity of the biofilm structure, and greatly improve the resistance of sheep sperm to freezing damage.

The invention discloses a medicine for preventing or treating liver toxic and side effects of osimertinib, and belongs to the technical field of medicines. Aiming at liver toxic and side effects caused by osimertinib, the invention provides an effective therapeutic drug, and the autophagy inhibitor relieves death caused by excessive activation of an autophagy pathway in hepatocytes by inhibiting autophagy activated by osimertinib, so that hepatotoxicity caused by osimertinib is relieved. The autophagy inhibitor and osimertinib are combined, so that the survival rate of hepatocytes can be remarkably improved, and liver injury caused in the osimertinib treatment process is reduced. The invention further provides novel application of the hydroxychloroquine or the S-adenosylmethionine in preparation of the medicine for preventing or treating the liver toxic and side effects of the osimertinib, the hydroxychloroquine or the S-adenosylmethionine has a remarkable treatment effect on liver injuries caused by the osimertinib, the medication safety of the hydroxychloroquine or the S-adenosylmethionine is high, and the hydroxychloroquine or the S-adenosylmethionine can be used for preparing the medicine for preventing or treating the liver toxic and side effects of the osimertinib. Good development prospects are realized.

The present invention aims to provide a chemical mechanical polishing (CMP) slurry for tungsten polishing, comprising: a chloroquine corrosion inhibitor, water, abrasive particles, a catalyst, a stabilizer, an oxidant, and a pH adjuster. The CMP slurry provided by the present invention can provide high tungsten polishing speeds and moderate silica polishing speeds. Most importantly, the composition exhibits low tungsten static corrosion, thereby improving the surface condition of the polished metal.

The application discloses a method for recycling 5-(N-ethyl-N-hydroxyethyl)-2-aminopentane, which comprises the following steps: 1) adjusting the pH value of wastewater to 12-14 to obtain a first mixed solution; 2) adding an organic solvent to the first mixed solution for extraction to obtain an organic phase containing 5-(N-ethyl-N-hydroxyethyl)-2-aminopentane; 3) performing vacuum concentration on the organic phase to obtain a concentrated solution; and 4) performing vacuum distillation on the concentrated solution, heating to 195-210 DEG C, and collecting a fraction at 190-200 DEG C to obtain 5-(N-ethyl-N-hydroxyethyl)-2-aminopentane, wherein the wastewater is generated in the post-treatment stage of an amination reaction of hydroxychloroquine synthesis, and the organic solvent is at least one selected from dichloromethane, toluene and ethyl acetate. Thus, 5-(N-ethyl-N-hydroxyethyl)-2-aminopentane in the wastewater can be recycled, the purity of the recycled substance reaches 98% or above, the recycled 5-(N-ethyl-N-hydroxyethyl)-2-aminopentane can be reused, and a large amount of production cost can be saved.

The present invention discloses the use of hydroxychloroquine sulfate in the preparation of a medicament for preventing and treating porcine reproductive and respiratory syndrome. The present invention discloses that hydroxychloroquine sulfate has a significant effect against porcine reproductive and respiratory syndrome virus. Its maximum non-toxic dose is 100 μM, which can effectively inhibit the infection and proliferation of porcine reproductive and respiratory syndrome virus and has a good therapeutic effect on PRRSV infection in piglets. It can be used as a medicament for preventing and treating porcine reproductive and respiratory syndrome and has good application prospects in the prevention and treatment of porcine reproductive and respiratory syndrome.

The invention discloses a composition with a tumor mitochondrial dual regulation effect, temperature-sensitive hydrogel and application, and belongs to the technical field of biological medicine, the composition is composed of a peroxide initiator and a mitochondrial autophagy inhibitor, the peroxide initiator is used for causing mitochondrial damage, and the mitochondrial autophagy inhibitor is used for causing mitochondrial autophagy. The mitochondrial autophagy inhibitor is used for inhibiting mitochondrial The peroxide initiator is indocyanine green, chlorin, iron oxide nanoparticles or Fe-MOFs (Metal-Organic Frameworks); the mitochondrial autophagy inhibitor is chloroquine, 3-methyladenosine or bajulomycin A1; the tumor is specifically melanoma; the combination of the peroxide initiator and the mitochondrial autophagy inhibitor can better inhibit the energy metabolism of tumor cells and inhibit the occurrence and development of tumors, and after the composition is delivered through the temperature-sensitive hydrogel carrier, the treatment effect of the composition on tumors is further improved.

The invention discloses application of hydroxychloroquine to improvement of gene editing efficiency. The invention provides novel application of hydroxychloroquine, namely application of hydroxychloroquine in improving gene editing efficiency of a gene editing reagent on a receptor biological material. In the prior art, a research of combining hydroxychloroquine and gene editing efficiency is not seen. The inventor of the invention finds that the gene editing efficiency can be remarkably improved by treating a receptor biological material with hydroxychloroquine and then transfecting a gene editing reagent. The method is easy and convenient to operate and wide in applicability, and a new way for improving the editing efficiency is developed by introducing exogenous small molecules instead of directly modifying a gene editing tool. The invention provides a basis for exploring an editing efficiency improvement strategy by adding exogenous molecules instead of modifying an editor mutant.

The invention provides a pancreatic cancer diagnosis and treatment integrated bionic nano material as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: preparing Fe-doped hollow mesoporous MnO2 spheres by taking mesoporous silica as a template, modifying the surfaces of the Fe-doped hollow mesoporous MnO2 spheres with polydopamine, stirring and adsorbing albumin paclitaxel / adriamycin and chloroquine, then mixing the Fe-doped hollow mesoporous MnO2 spheres with PANC02 cell membrane protein-loaded bionic liposome, and repeatedly extruding to prepare the pancreatic cancer diagnosis and treatment integrated bionic nano material. Aiming at the treatment requirement of improving PDAC prognosis, the bionic nanocomposite with ordered targeting and multi-dimensional TME remodeling effects is constructed, so that chemotherapy of PDAC is enhanced, related mechanisms are researched, theoretical and experimental foundations are expected to be laid for improving PDAC treatment resistance, and the bionic nanocomposite has important scientific significance and clinical application value for precise diagnosis and treatment of PDAC.

The present invention relates to compounds comprising formula I:          Amino Acid Sequence -(L)n- DMARD wherein the amino acid sequence comprises QKRAAYDQYGHAAFE-NH2 (SEQ ID NO: 1), DMARD is a disease modifying antirheumatic agent, L is a linker unit; - is a covalent bond and n is 0 or 1 and methods of using the compound for treatment of autoimmune diseases. In a preferred embodiment the DMARD is selected from Chloroquine and Hydroxychloroquine.

The application provides a preparation method and application of a double-membrane fusion targeted nano drug delivery system, a targeted material Cholesterol-PEG2000-RT modified liposome loaded with hydroxychloroquine is prepared, then the similarity of the liposome and the membrane component of the exosome is utilized, and the fusion of the two is realized through an extrusion method, so that the double-membrane fusion targeted drug delivery system for activating hepatic stellate cells is prepared. The double-membrane fusion targeted nano drug delivery system can not only exert the synergistic anti-hepatic fibrosis treatment effect of hydroxychloroquine and the exosome, but also can realize the specific targeted autophagy inhibition of hydroxychloroquine on activated hepatic stellate cells, so that the further proliferation and differentiation of the activated hepatic stellate cells are prevented, the generation of fibrosis-related proteins is reduced, the anti-hepatic fibrosis effect is exerted, and in addition, the genes and active factors carried by the exosome derived from bone marrow mesenchymal stem cells can exert the liver protection and synergistic anti-hepatic fibrosis effect, so that a new thought and method are provided for the clinical treatment of hepatic fibrosis.

The invention relates to the field of biological medicines, and particularly discloses application of hydroxychloroquine in preparation of medicines for preventing and treating immune myocarditis, inflammatory cardiomyopathy and complications thereof. Immune myocarditis is caused by immune response caused by infectious or non-infectious diseases, and inflammatory cardiomyopathy is cardiomyopathy caused by chronic myocarditis. The hydroxychloroquine can reduce chemotaxis from inflammatory cells to the heart, inhibit macrophages from generating chemotactic factors CXCL16 and infiltration of Th17 cells, NKT cells and T lymphocytes, inhibit cardiac inflammatory response, fibrosis and cardiac function damage, and improve cardiac remodeling and ventricular dilatation. Hydroxychloroquine can significantly reduce cardiovascular composite endpoint events of patients with inflammatory cardiomyopathy, improve cardiac functions of the patients, and reduce hs-cTnI, NT-proBNP, hs-CRP and levels of various plasma inflammatory factors. Clinical and basic research results show that the hydroxychloroquine can be used for treating and / or preventing human immune myocarditis and inflammatory cardiomyopathy, and has the potential of being developed into the medicine for clinically preventing and treating immune myocarditis and inflammatory cardiomyopathy.

The invention discloses an osthole compound pesticide composition for preventing and treating plant pathogenic fungi and application of the osthole compound pesticide composition. The composition comprises an effective component A and an effective component B, the effective component A is cnidium lactone, and the effective component B is eugenol, azoxystrobin or hydroxychloroquine. The composition is compounded by using the cnidium lactone and eugenol, the cnidium lactone and azoxystrobin as well as the cnidium lactone and hydroxychloroquine as effective components, so that the composition has an obvious synergistic effect on preventing and treating tea leaf spot and tomato gray mold, and the generation of drug resistance and drug resistance of plants can be delayed by compounding the effective components; more choices are provided for prevention and treatment of pathogenic fungi, and the bacillus subtilis has a wide application prospect in prevention and treatment of plant pathogenic fungi diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to a marker for evaluating the curative effect of hydroxychloroquine on treating IgA nephropathy and application of the marker. The marker for evaluating the curative effect of the hydroxychloroquine on the IgA nephropathy is a combination of any one or any two or any three or any four or five of D-ornithine, L-arginine, L-cysteine, L-cystine and D-cysteine. Based on the five markers, a combined prediction model is constructed, the model shows relatively high prediction performance, and an early-stage non-invasive screening method can be provided for clinic and is used for identifying IgAN patients with potential HCQ treatment ineffectiveness.

The invention discloses application of hydroxychloroquine sulfate in preparation of a medicine for preventing and treating porcine reproductive and respiratory syndrome. The hydroxychloroquine sulfate disclosed by the invention has a remarkable effect of resisting the porcine reproductive and respiratory syndrome virus. The maximum non-toxic dose of the compound is 100 mu M, and the compound can effectively inhibit infection and proliferation of porcine reproductive and respiratory syndrome virus and has a good treatment effect on piglet PRRSV infection. The compound can be used as a medicine for preventing and treating the porcine reproductive and respiratory syndrome, and has a very good application prospect in the aspect of preventing and treating the porcine reproductive and respiratory syndrome.

The present invention relates to a pharmaceutical composition for preventing or treating flavivirus infections. The invention provides a pharmaceutical composition. The pharmaceutical composition comprises at least one of gentamicin sulfate, netilmicin, tobramycin, paromomycin, amikacin, capreomycin, triflurazine, dihydrostreptomycin, hydroxychloroquine, thiolidazine hydrochloride, efavirenz, mitefonew, nystatin, micafungin, bleomycin, remistat, montelukast, norfloxacin, nedaplatin and cephalosporin, and the pharmaceutical composition is prepared from the following raw materials in parts by weight. It is possible to exhibit an excellent growth inhibition or inactivation effect on different species of flavivirus.

The invention discloses a spinetoram compound pesticide composition as well as a preparation method and application thereof. The composition comprises an effective component A and an effective component B, the effective component A is spinetoram, and the effective component B is allicin, carvacrol or hydroxychloroquine. The composition is compounded by the spinetoram, the allicin, the carvacrol and the hydroxychloroquine, and has an obvious synergistic effect on prevention and treatment of gray mold, tea leaf spot and peach gummosis. Therefore, a preparation product containing the composition can improve the control effect on gray mold, tea leaf spot disease and peach gummosis of vegetables such as tomatoes, reduce the drug use frequency and delay the generation of drug resistance, and has a wide application prospect in prevention and treatment of plant pathogenic fungal diseases.

The invention discloses a bridged biquinoline compound and a preparation method and application thereof.The compound has a certain killing effect on colon cancer cells, lung cancer cells, liver cancer cells, gastric cancer cells, cervical cancer cells and breast cancer cells, the killing effect on the colon cancer cells is especially obvious, and the killing effect on the colon cancer cells is remarkably superior to that of positive control drugs chloroquine and cis-platinum; in addition, the bridged biquinoline compound has small toxic and side effects, solves the problem of large toxic and side effects of traditional platinum antitumor drugs such as cis-platinum and the like, and can be prepared into antitumor drugs for application. The preparation method of the bridged biquinoline compound is simple and efficient, industrial production can be realized, and the bridged biquinoline compound has great application value in tumor resistance.

A composition for preventing or treating a TNF-α-related disease is disclosed. The composition includes hydroflumethiazide or a pharmaceutically acceptable salt thereof as an active ingredient. The composition can effectively inhibit the expression or activity of TNF-α and exhibits an excellent treatment effect compared to methotrexate (MTX) or hydroxychloroquine (HCQ), which are rheumatoid arthritis treatment agents currently on the market, and, thus, can be effectively used for prevention or treatment of a TNF-α-related disease.

Drug combinations, compositions including pharmaceutical compositions as well as methods of using and treating a viral infection, including one of the following: (1) atovaquone with a second group of substances consisting of ademetionine, albendazole, celastrol, cepharantine, chloroquine, cycloheximide, diethylstilbestrol, gemcitabine, homoharringtonine, hydroxy progesterone, imatinib, imipramine, indomethacin, ivermectin, niclosamide, raloxifene, sorafenib, and tipifarnib; or (2) cepharantine with a second group of substances consisting of ademetionine, albendazole, atovaquone, celastrol, chloroquine, cycloheximide, diethylstilbestrol, gemcitabine, homoharringtonine, hydroxy progesterone, imatinib, imipramine, indomethacin, ivermectin, raloxifene, sorafenib, and tipifarnib; or (3) one substance selected from a first group of substances consisting of ademetionine, albendazole, atovaquone, celastrol, cepharantine, chloroquine, cycloheximide, diethylstilbestrol, gemcitabine, homoharringtonine, hydroxy progesterone, imatinib, imipramine, indomethacin, ivermectin, raloxifene, sorafenib, tipifarnib in combination with a second group of substances selected from the group consisting of ademetionine, albendazole, celastrol, cepharantine, chloroquine, cycloheximide, diethylstilbestrol, gemcitabine, homoharringtonine, hydroxy progesterone, imatinib, imipramine, indomethacin, ivermectin, raloxifene, sorafenib, and tipifarnib.

A method for prevention or treatment of a viral-mediated infectious disease in a mammal. The mammal may be a human being. A therapeutic dose of a composition is administered, via an inhalation delivery apparatus, to the mammal. The composition includes microparticles and / or nanoparticles. The microparticles and / or nanoparticles include a first pharmaceutically active agent and a second pharmaceutically active agent. The first pharmaceutically active agent includes unfractionated heparin (UFH), Low Molecular Weight Heparin (LMWH), sulfated non-anticoagulant heparin (S-NACH) or combinations thereof. The second pharmaceutically active agent includes 10-30 mg of hydroxychloroquine in a form of hydroxychloroquine sulfate, 10-30 mg of favipiravir, or a combination thereof. The viral-mediated infectious disease is caused by one or more viruses in the mammal.

The invention provides a preparation method and application of a targeting chimera, and the preparation method comprises the following steps: lactoferrin introduces azido sugar into surface glycosyl through glycometabolism labeling, and DNA enzyme is subjected to conjugate modification through a coupling agent; the modified DNA enzyme, lactoferrin with surface glycosyl introduced and chloroquine are subjected to a click chemical reaction, and the targeted chimera is obtained; compared with the existing immune activator, the NucleOTAC chimera obtained by the invention can be used as the immune activator to significantly enhance the bioavailability and focus targeted enrichment capacity of DNA enzyme, prevent the main configuration B-type DNA of eDNA in NETs from being converted into Z-type DNA, destroy the immune escape mechanism of bacteria, reactivate the extracellular sterilization network of neutrophil and activate the body immunity; the method is simple and easy to implement, the preparation process is simple, the property is stable, efficient hydrolysis damage of a tuberculosis biological membrane can be achieved, and host anti-tuberculosis immunotherapy is activated.

The invention relates to the technical field of biological medicines, in particular to application of veratramine in preparation of lysosome capture inhibition preparations and antiviral preparations. It is found that veratramine can be captured by lysosome and accumulated in the lysosome, and veratramine can be used for preparing lysosome capture inhibition preparations. Veratrolamine has the characteristics of small toxic and side effects and high safety, and is obviously superior to the existing lysosome capture inhibitors such as chloroquine and the like.

The invention provides application of agomelatine in preparation of a medicine for treating sicca syndrome, and relates to the technical field of biomedicine, agomelatine is a novel anti-depression medicine, and the main action mechanism of agomelatine is that anti-depression and anti-anxiety effects are achieved by activating melatonin receptors (MT1 and MT2) and antagonizing a 5-HT2c receptor. According to the application, an 8w-old NOD mouse is selected as a sicca syndrome model mouse, and meanwhile, an ICR mouse is selected as a normal mouse of the same control. NOD mice are randomly divided into a blank control group, a hydroxychloroquine (HCQ) treatment group (50 mg / kg), a melatonin (MLT) treatment group (15 mg / kg) and an agomelatine (AGO) treatment group (50 mg / kg). And observing the disease degree of the sicca syndrome mouse after 4W treatment. A specific verification experiment proves that the agomelatine in the application can be used for remarkably improving the sicca syndrome.

The invention discloses a double-membrane independently wrapped nano drug delivery system for regulating macrophages and platelets. The nano drug delivery system comprises macrophage membrane coated nanoparticles and platelet membrane coated nanoparticles, the macrophage membrane coated nanoparticles are used for adjusting macrophage immune response and loaded with a Toll-like receptor 7 (TLR7) inhibitor, the platelet membrane coated nanoparticles are used for inhibiting abnormal activation of platelets and loaded with a G protein coupled receptor P2Y12 inhibitor, the TLR7 inhibitor comprises at least one of TJ-M2010-5, hydroxychloroquine, Enpatron and IMO-8400, and the TLR7 inhibitor comprises at least one of TJ-M2010-5, hydroxychloroquine, Enpatron and IMO-8400. The P2Y12 inhibitor is prepared from at least one of ticagrelor, clopidogrel, prasugrel and cangrelor. According to the double-membrane independently-wrapped nano drug delivery system, drugs are efficiently delivered to related damaged cells of an inflammation part by utilizing related cell tropism of two cell membranes, immune disorder caused by macrophage and platelet abnormality is inhibited, diseases induced by immune imbalance are treated, an immune microenvironment is regulated and controlled, and the drug delivery effect is improved. And a new direction is provided for treatment of immune diseases.